Chemo Combo Wins in Ovarian Cancer, But Single-Agent Therapy Still in the Game

(MedPage Today) -- SAN JUAN, PUERTO RICO -- A negative study in low-grade serous ovarian cancer might have uncovered a pathway toward more effective treatment for a large subgroup of patients, according to the NRG-GY019 trial. The randomized...
Source
MedPage Today
Opens original article in a new tab



